Avalo Therapeutics Files 8-K Report
Ticker: AVTX · Form: 8-K · Filed: Sep 9, 2024 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 8-K |
| Filed Date | Sep 9, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-events, financials
Related Tickers: AVLO
TL;DR
AVLO filed an 8-K on 9/9/24 covering other events and financials.
AI Summary
On September 9, 2024, Avalo Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. The company, formerly known as Cerecor Inc., is incorporated in Delaware and headquartered in Rockville, Maryland.
Why It Matters
This filing provides important updates on Avalo Therapeutics' corporate events and financial disclosures, which are crucial for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report and does not appear to contain any immediately alarming or significant negative news.
Key Numbers
- 001-37590 — SEC File Number (Identifies the company's filing with the SEC.)
- 45-0705648 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Registrant
- Cerecor Inc. (company) — Former company name
- September 9, 2024 (date) — Date of report
- Rockville, Maryland (location) — Principal executive offices
- Delaware (location) — State of incorporation
FAQ
What specific "Other Events" are detailed in this 8-K filing?
The provided text does not specify the exact 'Other Events' but indicates that this section is part of the filing.
What is the significance of the 'Financial Statements and Exhibits' section?
This section typically includes updated financial reports and supporting documents that provide insight into the company's financial health.
When did Cerecor Inc. change its name to Avalo Therapeutics, Inc.?
The filing states the date of the name change was November 2, 2011.
Where are Avalo Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 540 Gaither Road, Suite 400, Rockville, Maryland 20850.
What is the SIC code for Avalo Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 421 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2024-09-09 07:22:08
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 Par Value AVTX Nasdaq Capital Market
Filing Documents
- avtx-20240909.htm (8-K) — 25KB
- avaloinvestordeckseptemb.htm (EX-99.1) — 26KB
- avaloinvestordeckseptemb001.jpg (GRAPHIC) — 96KB
- avaloinvestordeckseptemb002.jpg (GRAPHIC) — 179KB
- avaloinvestordeckseptemb003.jpg (GRAPHIC) — 144KB
- avaloinvestordeckseptemb004.jpg (GRAPHIC) — 102KB
- avaloinvestordeckseptemb005.jpg (GRAPHIC) — 128KB
- avaloinvestordeckseptemb006.jpg (GRAPHIC) — 111KB
- avaloinvestordeckseptemb007.jpg (GRAPHIC) — 40KB
- avaloinvestordeckseptemb008.jpg (GRAPHIC) — 115KB
- avaloinvestordeckseptemb009.jpg (GRAPHIC) — 109KB
- avaloinvestordeckseptemb010.jpg (GRAPHIC) — 138KB
- avaloinvestordeckseptemb011.jpg (GRAPHIC) — 108KB
- avaloinvestordeckseptemb012.jpg (GRAPHIC) — 126KB
- avaloinvestordeckseptemb013.jpg (GRAPHIC) — 119KB
- avaloinvestordeckseptemb014.jpg (GRAPHIC) — 120KB
- avaloinvestordeckseptemb015.jpg (GRAPHIC) — 163KB
- avaloinvestordeckseptemb016.jpg (GRAPHIC) — 37KB
- avaloinvestordeckseptemb017.jpg (GRAPHIC) — 112KB
- avaloinvestordeckseptemb018.jpg (GRAPHIC) — 120KB
- avaloinvestordeckseptemb019.jpg (GRAPHIC) — 35KB
- avaloinvestordeckseptemb020.jpg (GRAPHIC) — 144KB
- avaloinvestordeckseptemb021.jpg (GRAPHIC) — 30KB
- avaloinvestordeckseptemb022.jpg (GRAPHIC) — 91KB
- avaloinvestordeckseptemb023.jpg (GRAPHIC) — 37KB
- 0001628280-24-039764.txt ( ) — 3493KB
- avtx-20240909.xsd (EX-101.SCH) — 2KB
- avtx-20240909_lab.xml (EX-101.LAB) — 21KB
- avtx-20240909_pre.xml (EX-101.PRE) — 12KB
- avtx-20240909_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On September 9, 2024, Avalo Therapeutics, Inc. (the "Company") posted on its website an updated investor presentation (the "Investor Presentation"). The Investor Presentation will be used from time to time in meetings with investors. A copy of the Investor Presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Investor Presentation. 104 The cover pages of this Current Report on Form 8-K, formatted in Inline XBRL. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALO THERAPEUTICS, INC. Date: September 9, 2024 By: /s/ Christopher Sullivan Christopher Sullivan Chief Financial Officer 2